Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc. is a specialty pharmaceutical company founded in 2013, with a focus on developing innovative products and therapeutics for pain management. The company's primary emphasis is on creating non-opioid products for underserved patients with back pain, aiming to improve efficacy and safety in treating these individuals. Semnur's novel injectable gel formulation, SP-102, has received fast track status from the FDA and is now in Phase 3 multi-center CLEAR Trial for Sciatica/Lumbar Radicular Pain. This development is particularly significant considering that more than 30 million people in the U.S. live with chronic low back and radicular sciatica pain, often with inadequate response to existing therapies like opioids and NSAIDs. The company's efforts are well-timed, as there is a growing need for highly effective analgesic and anti-inflammatory medications without the associated toxicity and tolerability challenges of NSAIDs and opioids. With approximately 60 percent of the chronic pain market being accounted for by opioid prescriptions, Semnur's focus on providing alternative pain therapies is essential. Venture Round investment of $6.00M led by Canaan Partners, Frazier Healthcare Partners, and Vivo Capital in August 2013 reflects investor confidence in Semnur's vision. In the United States, Semnur plans to develop and commercialize product candidates, either independently or in collaboration with partners. Additionally, the company aims to expand its market presence globally through select regional partnerships. As the demand for non-opioid pain management solutions continues to rise, Semnur Pharmaceuticals, Inc. is well-positioned to make a significant impact in the field of pain therapeutics.